JP2015510945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510945A5 JP2015510945A5 JP2015501852A JP2015501852A JP2015510945A5 JP 2015510945 A5 JP2015510945 A5 JP 2015510945A5 JP 2015501852 A JP2015501852 A JP 2015501852A JP 2015501852 A JP2015501852 A JP 2015501852A JP 2015510945 A5 JP2015510945 A5 JP 2015510945A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- paclitaxel
- combination
- twice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930012538 Paclitaxel Natural products 0.000 claims description 30
- 229960001592 paclitaxel Drugs 0.000 claims description 30
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 206010033128 Ovarian cancer Diseases 0.000 claims description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000002062 proliferating effect Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000003442 weekly effect Effects 0.000 claims description 10
- 208000030507 AIDS Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 description 10
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613258P | 2012-03-20 | 2012-03-20 | |
| US61/613,258 | 2012-03-20 | ||
| PCT/US2013/032962 WO2013142491A1 (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510945A JP2015510945A (ja) | 2015-04-13 |
| JP2015510945A5 true JP2015510945A5 (enExample) | 2016-05-12 |
| JP6373252B2 JP6373252B2 (ja) | 2018-08-15 |
Family
ID=48048255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501852A Active JP6373252B2 (ja) | 2012-03-20 | 2013-03-19 | オーロラキナーゼ阻害薬を使用する癌の治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20130303519A1 (enExample) |
| EP (1) | EP2827855B1 (enExample) |
| JP (1) | JP6373252B2 (enExample) |
| KR (1) | KR102128866B1 (enExample) |
| CN (1) | CN104271129A (enExample) |
| AU (1) | AU2013235275B2 (enExample) |
| CA (1) | CA2868024A1 (enExample) |
| EA (1) | EA036434B1 (enExample) |
| ES (1) | ES2746946T3 (enExample) |
| GE (2) | GEAP201813599A (enExample) |
| IL (1) | IL234686B (enExample) |
| IN (1) | IN2014DN08477A (enExample) |
| JO (1) | JO3630B1 (enExample) |
| MA (1) | MA37438A1 (enExample) |
| MX (1) | MX358411B (enExample) |
| MY (1) | MY175225A (enExample) |
| NZ (1) | NZ700744A (enExample) |
| PH (1) | PH12014502109A1 (enExample) |
| SG (2) | SG11201405621UA (enExample) |
| TN (1) | TN2014000387A1 (enExample) |
| TW (1) | TWI649082B (enExample) |
| UA (1) | UA117455C2 (enExample) |
| WO (1) | WO2013142491A1 (enExample) |
| ZA (1) | ZA201407551B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| JP2018502089A (ja) * | 2014-12-23 | 2018-01-25 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ |
| JP6786530B2 (ja) * | 2015-07-02 | 2020-11-18 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー |
| CN114681455A (zh) * | 2018-08-17 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| NZ192803A (en) | 1979-02-07 | 1984-08-24 | Hoffmann La Roche | Pyrimido-2-benzazepines and pharmaceutical compositions |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| TW486480B (en) | 1996-03-08 | 2002-05-11 | Zeneca Ltd | Azolobenzazepine derivatives and compositions and method of use thereof |
| WO1998028281A1 (en) | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| RU2198885C2 (ru) | 1997-09-29 | 2003-02-20 | Мейдзи Сейка Кайся Лтд. | Производные трициклического триазолобензазепина, способы их получения, фармацевтическая композиция и способ лечения аллергических заболеваний, промежуточные соединения и способы их получения |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| WO2000067754A1 (en) | 1999-05-12 | 2000-11-16 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| DK1318997T3 (da) | 2000-09-15 | 2006-09-25 | Vertex Pharma | Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer |
| HUP0400639A3 (en) | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them |
| SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (de) | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
| WO2003013545A1 (en) | 2001-08-09 | 2003-02-20 | Actelion Pharmaceuticals Ltd | Novel benzo-fused heterocycles as endothelin antagonisits |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| EP1718303A4 (en) | 2004-02-10 | 2010-09-01 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG |
| RS50568B8 (sr) | 2004-05-14 | 2019-08-30 | Millennium Pharm Inc | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze |
| JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
| JP2008526723A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
| MX2008008320A (es) | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Inhibidores de azaindol de aurora cinasas. |
| JP2009523784A (ja) | 2006-01-16 | 2009-06-25 | ジュビラント・オルガノシス・リミテッド | 酸不安定化合物の安定な医薬製剤およびその製造方法 |
| TW200744583A (en) | 2006-03-14 | 2007-12-16 | Ranbaxy Lab Ltd | Statin stabilizing dosage formulations |
| DE102006012301A1 (de) | 2006-03-15 | 2007-09-20 | Cemag-Anlagenbau-Dessau Gmbh | Herstellung von Zementklinker |
| US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| EP2077850A2 (en) | 2006-10-31 | 2009-07-15 | Achillion Pharmaceuticals, Inc. | Elvucitabine pharmaceutical compositions |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| US20110033461A1 (en) * | 2008-03-12 | 2011-02-10 | Vladimir Ratushny | Combination Therapy for the Treatment of Cancer |
| US20110212157A1 (en) | 2008-06-26 | 2011-09-01 | Anterios, Inc. | Dermal delivery |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| CN102770024A (zh) | 2010-02-19 | 2012-11-07 | 米伦纽姆医药公司 | 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式 |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
-
2013
- 2013-03-14 US US13/804,570 patent/US20130303519A1/en not_active Abandoned
- 2013-03-18 JO JOP/2013/0075A patent/JO3630B1/ar active
- 2013-03-19 SG SG11201405621UA patent/SG11201405621UA/en unknown
- 2013-03-19 IN IN8477DEN2014 patent/IN2014DN08477A/en unknown
- 2013-03-19 MY MYPI2014702635A patent/MY175225A/en unknown
- 2013-03-19 MX MX2014011324A patent/MX358411B/es active IP Right Grant
- 2013-03-19 CA CA2868024A patent/CA2868024A1/en not_active Abandoned
- 2013-03-19 KR KR1020147028776A patent/KR102128866B1/ko active Active
- 2013-03-19 SG SG10201607741RA patent/SG10201607741RA/en unknown
- 2013-03-19 EA EA201491727A patent/EA036434B1/ru not_active IP Right Cessation
- 2013-03-19 GE GEAP201813599A patent/GEAP201813599A/en unknown
- 2013-03-19 GE GEAP201313599A patent/GEP20186900B/en unknown
- 2013-03-19 AU AU2013235275A patent/AU2013235275B2/en active Active
- 2013-03-19 ES ES13714455T patent/ES2746946T3/es active Active
- 2013-03-19 WO PCT/US2013/032962 patent/WO2013142491A1/en not_active Ceased
- 2013-03-19 UA UAA201411324A patent/UA117455C2/uk unknown
- 2013-03-19 JP JP2015501852A patent/JP6373252B2/ja active Active
- 2013-03-19 NZ NZ700744A patent/NZ700744A/en not_active IP Right Cessation
- 2013-03-19 CN CN201380015806.1A patent/CN104271129A/zh active Pending
- 2013-03-19 EP EP13714455.6A patent/EP2827855B1/en active Active
- 2013-03-19 MA MA37438A patent/MA37438A1/fr unknown
- 2013-03-20 TW TW102109912A patent/TWI649082B/zh active
-
2014
- 2014-09-15 TN TNP2014000387A patent/TN2014000387A1/fr unknown
- 2014-09-16 IL IL234686A patent/IL234686B/en active IP Right Grant
- 2014-09-22 PH PH12014502109A patent/PH12014502109A1/en unknown
- 2014-10-17 ZA ZA2014/07551A patent/ZA201407551B/en unknown
-
2015
- 2015-09-03 US US14/844,270 patent/US10213436B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530280A5 (enExample) | ||
| JP2014512356A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| JP2013520442A5 (enExample) | ||
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2008528486A5 (enExample) | ||
| TW200533339A (en) | Therapeutic synergy of anti-cancer compounds | |
| JP2011079858A5 (enExample) | ||
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| JP2012509889A5 (enExample) | ||
| JP2016536352A5 (enExample) | ||
| JP2015517529A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2020523356A5 (enExample) | ||
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| JP2009515901A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| JP2014533277A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| JP2015510945A5 (enExample) | ||
| JP2015507020A5 (enExample) | ||
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака |